Pharma Manufacturing

Data quality has shifted from compliance checkbox to pharma's biggest strategic asset, ALCOA+ explains why.

LIMS implementation in pharma fails on trust, not technology, why workflow mismatch creates hidden compliance risk.

Digital twin is delivering real ROI in pharma manufacturing. The question in 2026 is not deployment — it's regulatory defensibility.

Pharma serialization and track-and-trace keep shifting for Indian exporters why infrastructure beats one-time projects in 2026.

A 4-step playbook for migrating from CSV to CSA, risk-tiering, retain/retire decisions, and inspection defense for Indian pharma.

7 of 10 pharma MES projects get worked around in two years. Here's why, what survivors do differently, and where it's discussed at PMITS, 7 July.

Inside PMITS Ahmedabad, 7 July 2026. 130 delegates, India's top pharma manufacturing IT leaders, on MES, CSA, GAMP 5, and the paperless transition.

GAMP 5 Ed.2 recalibrates MES validation around risk, not paperwork. Here's the practical classification framework pharma teams need.

mRNA vaccines proved the science works. Scaling RNA therapeutics manufacturing is the real challenge, 7 bottlenecks the industry faces.

1,200+ nanomedicine trials are active globally, yet only 50-80 have reached approval. The regulatory gaps pharma must solve.